PDCD1 and neoplasm: Immunotherapy and molecular individualization immune checkpoint inhibitors (ICIs), specifically programmed cell death protein 1 (PD-1) blockade (e.g., pembrolizumab), have demonstrated response rates in certain AS cohorts, potentially linked to an elevated tumor mutation burden (TMB) or specific gene fusions (frequent in post-radiation and head-and-neck subtypes).